Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths globally. Sorafenib is the only first-line systemic drug for advanced HCC, but it has very limited survival benefits because patients treated with sorafenib either suffer from side effects or show disease progressio...

Full description

Saved in:
Bibliographic Details
Published in:Gene Expr
Main Authors: Reyes, Ryan, Wani, Nissar A., Ghoshal, Kalpana, Jacob, Samson T., Motiwala, Tasneem
Format: Artigo
Language:Inglês
Published: Cognizant Communication Corporation 2016
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5296238/
https://ncbi.nlm.nih.gov/pubmed/27938509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3727/105221616X693855
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items